相似文献
1
Venom immunotherapy: safety and tolerability of the build-up phase with depot versus aqueous preparations.
Clin Exp Allergy. 2022 Oct;52(10):1230-1233. doi: 10.1111/cea.14209. Epub 2022 Jul 29.
2
Good tolerability when switching from an aqueous ultra-rush Hymenoptera venom immunotherapy to a depot preparation.
Allergy. 2020 Jul;75(7):1800-1802. doi: 10.1111/all.14227. Epub 2020 Mar 3.
3
Ultrarush immunotherapy in patients with Hymenoptera venom allergy.
J Allergy Clin Immunol. 2001 May;107(5):928-9. doi: 10.1067/mai.2001.115138.
4
Evaluation of the safety of a protocol for switching venom immunotherapy products.
Ann Allergy Asthma Immunol. 2018 Apr;120(4):429-430. doi: 10.1016/j.anai.2018.01.026. Epub 2018 Feb 2.
5
Purified vs. nonpurified venom immunotherapy.
Curr Opin Allergy Clin Immunol. 2010 Aug;10(4):330-6. doi: 10.1097/ACI.0b013e328339f2d1.
6
Simultaneous up-dosing of bee and vespid venom immunotherapy is safe.
Allergy. 2020 Mar;75(3):721-723. doi: 10.1111/all.14079. Epub 2019 Oct 23.
7
Adverse reactions to venom immunotherapy.
Ann Allergy. 1981 Dec;47(6):435-9.
8
The safety of initiating Hymenoptera immunotherapy at 1 microg of venom extract.
J Allergy Clin Immunol. 2009 Aug;124(2):379-81. doi: 10.1016/j.jaci.2009.05.026. Epub 2009 Jun 27.
9
[Hyper-accelerated immunotherapy with Hymenoptera venoms].
Allerg Immunol (Paris). 1987 Apr;19(4):156-8, 160, 162-3.
10
[Results of hyposensitization with bee and wasp venom].
Z Erkr Atmungsorgane. 1986;166(1):119-24.
本文引用的文献
1
β-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy.
Allergy. 2021 Jul;76(7):2166-2176. doi: 10.1111/all.14785. Epub 2021 Mar 11.
2
Hymenoptera Venom Allergy: Management of Children and Adults in Clinical Practice.
J Investig Allergol Clin Immunol. 2019;29(3):180-205. doi: 10.18176/jiaci.0310. Epub 2018 Sep 5.
3
EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy.
Allergy. 2018 Apr;73(4):744-764. doi: 10.1111/all.13262. Epub 2017 Dec 5.
4
Stinging insect allergy: current perspectives on venom immunotherapy.
J Asthma Allergy. 2015 Jul 23;8:75-86. doi: 10.2147/JAA.S62288. eCollection 2015.
5
Safety of hymenoptera venom immunotherapy: a systematic review.
Expert Opin Pharmacother. 2011 Nov;12(16):2527-32. doi: 10.1517/14656566.2011.616494. Epub 2011 Sep 2.
6
Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
J Allergy Clin Immunol. 2010 Jul;126(1):105-11.e5. doi: 10.1016/j.jaci.2010.04.025. Epub 2010 Jun 12.
7
Higher frequency of early local side effects with aqueous versus depot immunotherapy for hymenoptera venom allergy.
J Investig Allergol Clin Immunol. 2004;14(2):127-33.
8
Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology.
Allergy. 2000 Nov;55(11):1005-10. doi: 10.1034/j.1398-9995.2000.00587.x.
9
Safety of venom immunotherapy administered by a cluster schedule.
J Allergy Clin Immunol. 1992 Jun;89(6):1198-9. doi: 10.1016/0091-6749(92)90306-m.
Zotero 插件